Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Xylosyltransferase 2 (XYLT2)
- Target
- XYLT2
- Molecular classification
- Enzyme, Glycosyltransferase, Transferase
01
Overview
Xylosyltransferase 2 is an enzyme encoded by the *XYLT2* gene, responsible for catalyzing the transfer of xylose from UDP-xylose to specific serine residues in core proteins, thereby initiating the biosynthesis of glycosaminoglycan chains found in major proteoglycans such as chondroitin sulfate, heparan sulfate, heparin, and dermatan sulfate. This enzyme is ubiquitous and plays an essential role in proteoglycan formation and extracellular matrix composition. Mutations in this gene are implicated in spondyloocular syndrome and pseudoxanthoma elasticum, and increased activity in serum serves as a diagnostic marker for sclerotic activity in systemic sclerosis. Proteomic and biomarker studies suggest its activity is relevant across several connective tissue and metabolic diseases, with circulating levels influenced by platelet and liver function.
- Other names
- Xylosyltransferase IIPeptide O-xylosyltransferase 1XT-IIXylT-IIXT2XYLT2
02
Mechanism of action
Not established for any approved drugs. Inhibition would reduce proteoglycan biosynthesis by preventing glycosaminoglycan chain initiation.
03
Biological functions
Catalyzes transfer of xylose from UDP-xylose to specific serine residues in core proteinsInitiates biosynthesis of glycosaminoglycan chains in proteoglycans (including chondroitin sulfate, heparan sulfate, heparin, dermatan sulfate)Key role in glycosaminoglycan metabolism and biosynthesisProteoglycan formation, extracellular matrix organization
04
Disease associations
Spondyloocular syndromePseudoxanthoma elasticumDiagnostic marker for systemic sclerosis (scleroderma) sclerotic activityMay serve as a biomarker in platelet and liver-related diseases
05
Safety considerations
Potential off-target effects from glycosyltransferase inhibition would impact extracellular matrix formation, possibly affecting connective tissue integrity, wound healing, and organ function.Mutations can lead to genetic syndromes and connective tissue disorders
06
Biomarkers
Elevated serum xylosyltransferase 2 activity can be used as a biomarker for sclerotic activity in systemic sclerosis and may inform disease processes in platelet/liver dysfunction
Beyond the preview
Go deeper on Xylosyltransferase 2 (XYLT2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xylosyltransferase 2 (XYLT2).